Cytosorbents 1/3/2025 Earnings Report

Cytosorbents EPS Results

• Actual EPS: -$0.08
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Cytosorbents Revenue Results

• Actual Revenue: $8.61 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cytosorbents Announcement Details

• Date: 1/3/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Cytosorbents (NASDAQ:CTSO), founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America. In the United States, the device received Emergency Use Authorization from the U.S. Food and Drug Administration for treatment of critically ill COVID-19 patients exhibiting a cytokine storm. Clinicians integrate CytoSorb into standard extracorporeal circuits such as continuous renal replacement therapy (CRRT) and cardiopulmonary bypass to optimize blood purification protocols in intensive care units.

Beyond its core sorbent technology, Cytosorbents is advancing a pipeline of next-generation products aimed at drug overdose management and vaccine adjuvant development. The company’s R&D efforts leverage proprietary polymer bead platforms to broaden the applications of hemoadsorption in pharmaceutical safety and immunotherapy. With a global sales and distribution network and strategic partnerships in key markets, Cytosorbents continues to expand clinical evidence to support broader adoption of its blood purification solutions.